The company’s circuit begins September 15 in Boston at the 9th Annual Neuropsychiatric Drug Development Summit. Chief Medical Officer Magali Haas, MD-PhD, and Co-Founder Dr. Jackie von Salm will join a panel investigating the precise role of neuroplasticity in psychedelic efficacy. The firm shifts its focus to neurodegenerative disease shortly after, with Haas and EVP of Corporate Development Scott Rairigh attending the 15th International Conference on Frontotemporal Dementias in Philadelphia this October.
In section Releases
Psilera Maps Out Fall Circuit to Advance Neuroplastogen Pipeline
Tampa-based biopharmaceutical firm Psilera will deploy its executive and scientific leadership across four major global forums this autumn. The team plans to present fresh clinical data on PSIL-006, a proprietary neuroplastogen designed to replicate the therapeutic benefits of traditional psychedelics while stripping away hallucinogenic side effects.
Following a mid-October appearance at the University of Wisconsin-Madison Psychedelic Symposium, the team concludes its schedule in London at Jefferies HealthCare Week. There, Co-Founders Chris Witowski, PhD, and Jackie von Salm will engage with European investors and development partners to accelerate the clinical trajectory of the PSIL-006 program. Leadership remains open to one-on-one meetings throughout the tour to discuss the company’s broader mission of engineering non-hallucinogenic, next-generation mental health therapeutics.
Comments (0)
No comments yet. Be the first!